EP3618856A4 - Multi-indication mrna cancer immunotherapy - Google Patents

Multi-indication mrna cancer immunotherapy Download PDF

Info

Publication number
EP3618856A4
EP3618856A4 EP18795120.7A EP18795120A EP3618856A4 EP 3618856 A4 EP3618856 A4 EP 3618856A4 EP 18795120 A EP18795120 A EP 18795120A EP 3618856 A4 EP3618856 A4 EP 3618856A4
Authority
EP
European Patent Office
Prior art keywords
indication
cancer immunotherapy
mrna cancer
mrna
immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18795120.7A
Other languages
German (de)
French (fr)
Other versions
EP3618856A1 (en
Inventor
Michael J. P. LAWMAN
Patricia D. Lawman
Meghan GENTILINI
Vijay RAMIYA
Marina Victor Abdelmaseeh BASTAWROUS
Michael J. Shamblott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphogenesis Inc
Original Assignee
Morphogenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/583,599 external-priority patent/US10682401B2/en
Application filed by Morphogenesis Inc filed Critical Morphogenesis Inc
Publication of EP3618856A1 publication Critical patent/EP3618856A1/en
Publication of EP3618856A4 publication Critical patent/EP3618856A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP18795120.7A 2017-05-01 2018-04-30 Multi-indication mrna cancer immunotherapy Withdrawn EP3618856A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/583,599 US10682401B2 (en) 2015-05-19 2017-05-01 Multi-indication mRNA cancer immunotherapy
PCT/US2018/030142 WO2018204234A1 (en) 2017-05-01 2018-04-30 Multi-indication mrna cancer immunotherapy

Publications (2)

Publication Number Publication Date
EP3618856A1 EP3618856A1 (en) 2020-03-11
EP3618856A4 true EP3618856A4 (en) 2021-02-24

Family

ID=64016702

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18795120.7A Withdrawn EP3618856A4 (en) 2017-05-01 2018-04-30 Multi-indication mrna cancer immunotherapy

Country Status (2)

Country Link
EP (1) EP3618856A4 (en)
WO (1) WO2018204234A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021013125A2 (en) * 2019-01-04 2021-09-28 Etherna Immunotherapies Nv MRNA VACCINE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187407A1 (en) * 2015-05-19 2016-11-24 Morphogenesis, Inc. Cancer vaccine comprising mrna encoding a m-like-protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348015B2 (en) * 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
US7795020B2 (en) * 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
DK3113793T3 (en) * 2014-03-06 2021-01-18 Morphogenesis Inc DNA VECTOR AND TRANSFORMED TUMOR CELL VACCINES
SG10201910433VA (en) * 2015-05-15 2020-01-30 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187407A1 (en) * 2015-05-19 2016-11-24 Morphogenesis, Inc. Cancer vaccine comprising mrna encoding a m-like-protein

Also Published As

Publication number Publication date
WO2018204234A1 (en) 2018-11-08
EP3618856A1 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
EP3624810A4 (en) Nano-enabled immunotherapy in cancer
EP3866813A4 (en) Combinatorial cancer immunotherapy
EP3240801A4 (en) Combination tumor immunotherapy
IL269810A (en) Combinatorial cancer immunotherapy
EP3286361A4 (en) Cancer neoepitopes
EP3422945A4 (en) Enhanced cancer immunotherapy by microneedle patch-assisted delivery
EP3289631A4 (en) Antenna mount
EP3280738A4 (en) Cancer neoepitopes
EP3247408A4 (en) Compositions and methods for cancer immunotherapy
EP3500966A4 (en) Immunotherapy markers and uses therefor
EP3597766A4 (en) Novel biomarker for cancer immunotherapy
EP3107566A4 (en) Biomarker directed multi-target immunotherapy
EP3292140A4 (en) Cancer immunotherapeutic
EP3500262A4 (en) Compositions and methods for cancer immunotherapy
EP3892333A4 (en) Tumor combined immunotherapy
HK1258387A1 (en) Targeting mda-5 activation for cancer immunotherapy
EP3618190A4 (en) Antenna
EP3823639A4 (en) Msc- and exosome-based immunotherapy
EP3310915A4 (en) Tumor immunotherapy
EP3265179A4 (en) Beta-catenin inhibitors in cancer immunotherapy
EP3589732A4 (en) Detecting prostate cancer
EP4045054A4 (en) Nano-enabled immunotherapy in cancer
IL289006A (en) Combination cancer immunotherapy
EP3576746A4 (en) Cancer therapeutic
EP4025204A4 (en) Cancer immunotherapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LAWMAN, MICHAEL, J. P.

Inventor name: RAMIYA, VIJAY

Inventor name: SHAMBLOTT, MICHAEL, J.

Inventor name: LAWMAN, PATRICIA, D.

Inventor name: BASTAWROUS, MARINA VICTOR, ABDELMASEEH

Inventor name: GENTILINI, MEGHAN

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017003

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210126

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20210120BHEP

Ipc: A61P 35/00 20060101ALI20210120BHEP

Ipc: A61K 39/00 20060101AFI20210120BHEP

Ipc: A61K 39/02 20060101ALI20210120BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220524